|

Quizartinib Clinical Trials

6 actively recruiting trials across 3 locations

▼ -1 trial since May 2026

Also known as: AC-220, AC010220, AC220, Test Product, Vanflyta

Pipeline

Phase 1: 2Phase 3: 1Phase 1/2: 3

Top Sponsors

  • M.D. Anderson Cancer Center4
  • Kura Oncology, Inc.1
  • Daiichi Sankyo1

Indications

  • Cancer6
  • Acute Myeloid Leukemia5
  • Refractory Acute Myeloid Leukemia3
  • Recurrent Acute Myeloid Leukemia3
  • Recurrent Myelodysplastic Syndrome2

Houston, Texas4 trials

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 1/2
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

The University of Texas M. D. Anderson Cancer Center

Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 1/2
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 1/2

Goodyear, Arizona1 trial

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

City of Hope Phoenix

Phase 3

Phoenix, Arizona1 trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Mayo Clinic - Phoenix

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.